ReviewHuman vaccines & immunotherapeutics2022
Advances in the progress of monoclonal antibodies for rabies.
Review in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Article
- Safety and operational feasibility of single versus cocktail rabies monoclonal antibodies for post-exposure prophylaxis in a resource-limited setting.PLoS neglected tropical diseases · 2026Observational
- Rabies post-exposure prophylaxis in India: a SWOT analysis.Therapeutic advances in vaccines and immunotherapy · 2026Review
- Manufacturability is access: redesigning antibody production for equitable pediatric access in LMICs.Frontiers in pediatrics · 2026Article
- Review
- A review of post-exposure strategies for high-consequence viral pathogens in the laboratory.Clinical microbiology reviews · 2025Review
- Article
- Research trends in anti-rabies virus monoclonal antibody: A bibliometric analysis.Human vaccines & immunotherapeutics · 2025Article
- The Clinical Advantages of Anti-Rabies Monoclonal Antibodies in Post-Exposure Prophylaxis - Worldwide, 2016-2025.China CDC weekly · 2025Article
- Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations.Cell host & microbe · 2025Article
- Use of Rabies Monoclonal Antibodies in an Abandoned Newborn.Indian journal of pediatrics · 2025Article
- Infection and Prevention of Rabies Viruses.Microorganisms · 2025Review
- Establishment of rapid saturation mutagenesis and screening methods for improving the neutralizing activity of monoclonal antibodies.Frontiers in immunology · 2025Article
- Rabies in rural northeast India: A case report emphasising the urgency of the One Health approach.One health (Amsterdam, Netherlands) · 2024Article
- Development of novel canine phage display-derived neutralizing monoclonal antibody fragments against rabies virus from immunized dogs.Scientific reports · 2024Article
- Safety assessment of the world's first novel cocktail of two monoclonal antibodies in WHO category-III animal-bite patients.Journal of family medicine and primary care · 2024Article
- Review
- Review
- A new dawn for monoclonal antibodies against antimicrobial resistant bacteria.Frontiers in microbiology · 2022Review
- Assessing the Safety of a Novel Monoclonal Antibody Cocktail for Postexposure Prophylaxis in Category III Animal Exposures.International journal of applied & basic medical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rabies is a highly fatal zoonotic disease caused by the rabies virus invading the central nervous system. When suspected of exposure to the rabies virus, post-exposure prophylaxis should be administered as soon as possible. Monoclonal antibodies (mAbs) neutralizing the rabies virus could be better in human rabies post-exposure prophylaxis than equine or human rabies immune globulin in terms of supply, cost, and efficacy. This article reviews anti-rabies mAbs produced by multiple techniques, and the results of clinical trials for anti-rabies mAbs cocktails recognizing non-overlapping epitopes are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.